FDA approves Korlym for hyperglycemia in patients with endogenous Cushing’s syndrome
On Feb. 17, the U.S. Food and Drug Administration (FDA) announced the approval of Korlym (mifepristone) to control hyperglycemia in adults with endogenous Cushing’s…



